Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 316 AL 330

Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment

Andreozzi E, Yagi T, Wildsmith K, Rawal S, Horie K, Boyd P, Takahashi E, Barthélemy NR, Aluri J, Charil A, Reilhac A, Gordon BA, Flores S, Verbel D, Sauter N, Benzinger TLS, McDade E, Mummery C; Dominantly Inherited Alzheimer Network (DIAN); Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU); Zhou J, Bateman RJ, Reyderman L.

Alzheimers Res Ther. 2026 Apr 10;18(1):87. doi: 10.1186/s13195-026-02047-y.

[Alzheimer's disease and other neurocognitive disorders - epidemiology and new diagnostic criteria]

Borgh Skillbäck T, Palmqvist S, Eriksdotter M, Skoog I, Kern S.

Lakartidningen. 2026 May 19;123:25140.

Digital biomarkers in early Alzheimer's disease from wearable or portable technology: A scoping review

Gramkow MH, Gleerup HSC, Simonsen AH, Waldemar G, Frederiksen KS.

J Neurol Sci. 2026 Feb 15;481:125734. doi: 10.1016/j.jns.2026.125734. Epub 2026 Jan 6.

Diagnostic performance of salivary markers of Alzheimer's disease: A systematic review

Borelli PV, Machado L, Carello-Collar G, Ferreira PCL, Lourenço de Lima AMD, Bellaver B, Pascoal TA, Benedet AL, Ashton NJ, Zimmer ER, Borelli WV.

Alzheimers Dement. 2026 Apr;22(4):e71248. doi: 10.1002/alz.71248.

Integration over reduction: multimodal PET and fluid biomarkers in Alzheimer's disease and beyond

Bluma M, Chiotis K, Nordberg A.

Curr Opin Neurol. 2026 Apr 1;39(2):176-184. doi: 10.1097/WCO.0000000000001462. Epub 2026 Feb 23.

Advances in ultrasensitive detection technologies for blood-based biomarkers of Alzheimer's disease

Mou Y, Sun C, Deng K, Lin F, Yang Z, Wang Y, Deng X, Yang F, Hu X, Jiang Q.

J Mater Chem B. 2026 Apr 29;14(16):4848-4873. doi: 10.1039/d5tb02633d.

Therapeutic Landscape of Early Symptomatic Alzheimer's Disease Translated into Everyday Practice for Geriatric Providers

Bailey-Taylor MJ, Morrow P, Hendrix J, Galluzzi KE, Sharafsaleh G.

Clin Interv Aging. 2026 May 12;21:585263. doi: 10.2147/CIA.S585263. eCollection 2026.

Associations of cortisol with Alzheimer's disease fluid and neuroimaging biomarkers: A systematic review

Holleman J, Toopchiani S, Robinson O, Kåreholt I, Kivipelto M, Middleton L, Solomon A, Udeh-Momoh CT, Sindi S.

Front Neuroendocrinol. 2026 Apr;81:101246. doi: 10.1016/j.yfrne.2026.101246. Epub 2026 Mar 17.

CTAD 2025: Key trends redefining therapeutic and diagnostic strategies in Alzheimer's disease

Yuan M, Zhou HY.

J Alzheimers Dis. 2026 May;111(1):56-62. doi: 10.1177/13872877261430764. Epub 2026 Mar 15.

Eligibility for lecanemab treatment in a French memory clinic setting

Vrillon A, Götze K, Dumurgier J, Cognat E, Hourrègue C, Munoz-Musat E, Decaix T, Hugon J, Estrada J, Sebbagh M, Bouaziz-Amar É, Lilamand M, Paquet C.

J Neurol. 2026 Mar 23;273(4):228. doi: 10.1007/s00415-026-13760-x.

Analytical Methods for Fluid Biomarkers in Alzheimer's Disease from Discovery to Clinical Implementation

Agnello L, Dominici R, Gambino CM, Scazzone C, Ciaccio M.

Int J Mol Sci. 2026 May 18;27(10):4518. doi: 10.3390/ijms27104518.

Should all MCI with Alzheimer's biological diagnosis receive anti-amyloid therapy?

Rossini PM, Pappalettera C.

Cell Death Dis. 2026 Feb 10;17(1):212. doi: 10.1038/s41419-026-08456-z.

Tau proteoforms as plasma biomarkers in Alzheimer's disease: mechanisms, measurement, and medicine

Kim E, Lee J, Han D.

Expert Rev Proteomics. 2026 Jan-Feb;23(1-2):1-11. doi: 10.1080/14789450.2025.2611853. Epub 2026 Jan 5.

A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease

Chen T, Hutchison RM, Rubel C, Murphy J, Xie J, O'Gorman J, Dent G, Molenberghs G, Sormani MP, Hendrix S, Hansson O, Aisen P, Haeberlein SB, Tian Y.

J Prev Alzheimers Dis. 2026 Feb;13(2):100458. doi: 10.1016/j.tjpad.2025.100458. Epub 2026 Jan 1.

Altered locus coeruleus links to atrophy and hypometabolism in individuals with high Alzheimer's disease biomarkers

Foyard E, Blanchard T, Landeau B, Chauveau L, Naveau M, Poisnel G, Bui E, Chetelat G, de Flores R; Medit‐Ageing Research Group.

Alzheimers Dement. 2026 Mar;22(3):e71212. doi: 10.1002/alz.71212.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias